NVIDIA (NVDA) remains a high-conviction core holding as it transitions into a platform company, with the next-generation Vera Rubin infrastructure launch in H2 2026 supporting a massive $1 trillion revenue target. In the pharmaceutical sector, Eli Lilly (LLY) and Novo Nordisk (NVO) offer software-like margins and "Big Tech" scale revenue, specifically driven by the projected $45 billion in sales for Terzepatide and the upcoming Retatrutide catalyst. Investors seeking alternatives to the semiconductor incumbents should watch Cerebras Systems, which recently gained significant validation through a major inference chip partnership with Amazon (AMZN). Within the private markets, Anthropic is emerging as a critical national security asset with a $330 billion valuation, while the retail brand Quince represents a top-tier opportunity in AI-driven, capital-efficient e-commerce. Conversely, exercise extreme caution with private equity-backed software firms from the 2018–2022 era, as experts warn of potential 60–80% losses in recovery rates due to AI disruption.

Based on the transcript from TBPN (March 16, 2026), here are the investment insights and asset mentions extracted from the discussion.

NVIDIA (NVDA)

The discussion centered on NVIDIA’s dominant position as a "platform company" rather than just a chip manufacturer, highlighted by the GTC 2026 conference.

• Revenue Targets: CEO Jensen Huang reportedly projected $1 trillion in revenue through 2030.
• Product Cycle: The next-generation Vera Rubin AI infrastructure is expected to be available in H2 2026, with large-scale deployments beginning in early 2027.
• Software Moat: The 20th anniversary of CUDA was noted as the foundational "revolutionary invention" that maintains their competitive edge.
• Market Dynamics: Analysts noted "negative depreciation" for H100 chips, which are trading above launch prices in secondary markets due to extreme supply constraints.

Takeaways

• Bullish Sentiment: The "Super Bowl of Semiconductors" reinforces NVIDIA's role as the essential layer for the $100 trillion global industry.
• Supply Bottleneck: Demand continues to exceed supply significantly; relief is not expected until at least 2028.

Anthropic

The company is discussed as a major player in the "physical AI" and national security space, with its valuation reaching massive heights.

• Valuation: Reported at over $330 billion, with secondary markets rumored to be trading at nearly double that.
• Government Integration: The Pentagon is reportedly using Claude for intelligence data interpretation and strike planning in international conflicts.
• Compute Scale: Anthropics' target for 2026 is roughly 5 gigawatts of compute capacity.

Takeaways

• National Security Asset: The discussion suggests Anthropic is moving toward becoming a "national security project," making it a critical piece of US technological sovereignty.
• Secondary Market Heat: Extreme demand for shares indicates high investor confidence in their "reasoning" models (Claude 5.3/5.4).

Quince

A "direct-to-consumer" (DTC) retail giant backed by 8VC that has reached a $10 billion valuation.

• Performance: The company grew 100% year-over-year and is currently cash-generative at a multi-billion dollar scale.
• Efficiency: Quince is described as having the "world's most efficient supply chain," utilizing AI to maintain low operating expenses and high repeat purchase rates (Top 10 in the US).

Takeaways

• DTC Winner: Quince has survived the "graveyard" of Silicon Valley e-commerce by focusing on capital efficiency rather than high-burn customer acquisition.
• Investment Theme: Look for "full-stack" retailers that own the supply chain and use AI for margin expansion rather than just front-end marketing.

Cerebras Systems

A semiconductor competitor that is gaining significant traction against the incumbent (NVIDIA).

• AWS Partnership: Amazon announced a major inference chip deal with Cerebras, providing a massive validation of their "wafer-scale" technology.
• Performance: Their hardware is noted for providing "instant" answers in coding and LLM applications, which is driving high user retention.

Takeaways

• NVIDIA Alternative: Cerebras is proving to be a viable alternative for hyperscalers (like AWS) looking to diversify their hardware stacks.

Eli Lilly (LLY) / Novo Nordisk (NVO)

The "Big Pharma" sector is seeing a massive revenue boom driven by next-generation peptides.

• Revenue Projections: Terzepatide (Mounjaro/Zepbound) is projected to do $45 billion in global sales in 2026.
• Market Comparison: For context, global iPhone sales are roughly $230 billion; these drug sales are reaching "Big Tech" revenue scales.
• Pipeline: Retatrutide (3rd gen peptide) is being discussed as the next major catalyst for weight loss and metabolic health.

Takeaways

• High Margins: Once manufacturing plants are scaled, these drugs offer software-like margins with massive, inelastic demand.
• Placebo Effect: The "Retatrutide" craze is so high that users are reporting "placebo" weight loss, indicating extreme brand power and consumer desire.

Investment Themes & Sector Insights

1. The "Physical AI" Arms Race

• Key Players: Tesla (Elonverse) and Travis Kalanick’s new ventures.
• Insight: Investors are looking for an "indexed approach" to physical AI. If a company isn't working as hard as Elon or Travis's teams, their RSUs (stock options) are considered high-risk or "low value."

2. Private Credit & Equity "Arrogance"

• Risk Factor: Apollo’s John Zito warned that private market marks (valuations) are currently "wrong."
• Insight: Small-to-mid-sized software companies bought via private equity (2018–2022) are high-risk. Expect recovery rates of only 20–40 cents on the dollar for these loans as AI disrupts their profit pools.

3. Data Center & Power Constraints

• Bottleneck: The constraint has shifted from just GPUs to Power and Land.
• Insight: "Inference Rationing" may become the norm. Companies will have to decide which departments get the "trillion-parameter" models and which use smaller, distilled models.

4. Biotech Democratization

• Trend: AI is lowering the "cognitive overhead" for drug discovery.
• Insight: The "domestication of biotechnology" (as predicted by Freeman Dyson) is happening. Individual entrepreneurs are now able to sequence DNA and design mRNA vaccines (e.g., the Paul Conyngham/dog cancer story) using LLMs as high-powered research tools.